Cargando…
Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common liver disease. It has a rapidly growing patient population owing to the increasing prevalence of obesity and type 2 diabetes. Patients with MASLD are prima...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672694/ https://www.ncbi.nlm.nih.gov/pubmed/38004284 http://dx.doi.org/10.3390/life13112144 |
_version_ | 1785140451251060736 |
---|---|
author | Nagai, Koki Nagai, Kazuki Iwaki, Michihiro Kobayashi, Takashi Nogami, Asako Oka, Masanao Saito, Satoru Yoneda, Masato |
author_facet | Nagai, Koki Nagai, Kazuki Iwaki, Michihiro Kobayashi, Takashi Nogami, Asako Oka, Masanao Saito, Satoru Yoneda, Masato |
author_sort | Nagai, Koki |
collection | PubMed |
description | Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common liver disease. It has a rapidly growing patient population owing to the increasing prevalence of obesity and type 2 diabetes. Patients with MASLD are primarily treated by family physicians when fibrosis is absent or mild and by gastroenterologists/hepatologists when fibrosis is more advanced. It is imperative that a system for the appropriate treatment and surveillance of hepatocellular carcinoma be established in order to ensure that highly fibrotic cases are not overlooked among the large number of MASLD patients. Family physicians should check for viral hepatitis, autoimmune hepatitis, alcoholic liver disease, and drug-induced liver disease, and should evaluate fibrosis using NIT; gastroenterologists/hepatologists should perform liver biopsy, ultrasound elastography (260 units in Japan as of October 2023), and MR elastography (35 units in Japan as of October 2023). This review presents the latest findings in MASLD and the role, accuracy, and clinical use of NIT. It also describes the collaboration between Japanese primary care and gastroenterologists/hepatologists in Japan in the treatment of liver diseases, including MASLD. |
format | Online Article Text |
id | pubmed-10672694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106726942023-10-31 Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review Nagai, Koki Nagai, Kazuki Iwaki, Michihiro Kobayashi, Takashi Nogami, Asako Oka, Masanao Saito, Satoru Yoneda, Masato Life (Basel) Review Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common liver disease. It has a rapidly growing patient population owing to the increasing prevalence of obesity and type 2 diabetes. Patients with MASLD are primarily treated by family physicians when fibrosis is absent or mild and by gastroenterologists/hepatologists when fibrosis is more advanced. It is imperative that a system for the appropriate treatment and surveillance of hepatocellular carcinoma be established in order to ensure that highly fibrotic cases are not overlooked among the large number of MASLD patients. Family physicians should check for viral hepatitis, autoimmune hepatitis, alcoholic liver disease, and drug-induced liver disease, and should evaluate fibrosis using NIT; gastroenterologists/hepatologists should perform liver biopsy, ultrasound elastography (260 units in Japan as of October 2023), and MR elastography (35 units in Japan as of October 2023). This review presents the latest findings in MASLD and the role, accuracy, and clinical use of NIT. It also describes the collaboration between Japanese primary care and gastroenterologists/hepatologists in Japan in the treatment of liver diseases, including MASLD. MDPI 2023-10-31 /pmc/articles/PMC10672694/ /pubmed/38004284 http://dx.doi.org/10.3390/life13112144 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nagai, Koki Nagai, Kazuki Iwaki, Michihiro Kobayashi, Takashi Nogami, Asako Oka, Masanao Saito, Satoru Yoneda, Masato Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title | Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title_full | Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title_fullStr | Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title_full_unstemmed | Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title_short | Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review |
title_sort | frontiers of collaboration between primary care and specialists in the management of metabolic dysfunction-associated steatotic liver disease: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672694/ https://www.ncbi.nlm.nih.gov/pubmed/38004284 http://dx.doi.org/10.3390/life13112144 |
work_keys_str_mv | AT nagaikoki frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT nagaikazuki frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT iwakimichihiro frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT kobayashitakashi frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT nogamiasako frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT okamasanao frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT saitosatoru frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview AT yonedamasato frontiersofcollaborationbetweenprimarycareandspecialistsinthemanagementofmetabolicdysfunctionassociatedsteatoticliverdiseaseareview |